Intrahepatic Cholangiocarcinoma
- PMID: 31472907
- DOI: 10.1016/j.soc.2019.06.002
Intrahepatic Cholangiocarcinoma
Abstract
Intrahepatic cholangiocarcinoma (ICC) arises from the epithelial cells of the intrahepatic and extrahepatic bile ducts and occurs proximal to the segmental biliary ducts. Risk factors include chronic hepatitis and cirrhosis, biliary inflammatory diseases, and hepatobiliary flukes, although in most cases, no known risk factor is identified. ICC is highly aggressive, with long-term survival only observed in patients with a complete R0 surgical resection. Technical and physiologic resectability should be considered when performing an operative plan. Nodal involvement is among the most important prognostic factors associated with survival and a porta hepatis lymphadenectomy should be performed at the time of resection. Adjuvant chemotherapy can provide a significant survival benefit for patients with more advanced or aggressive tumors. Systemic, locoregional, and targeted therapies exist for patients with unresectable or metastatic disease.
Keywords: Cholangiocarcionma; Hepatobiliary; Intrahepatic cholangiocarcinoma.
Copyright © 2019 Elsevier Inc. All rights reserved.
Similar articles
-
Intra-arterial yttrium-90 radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment.Ann Surg Oncol. 2015 Sep;22(9):3102-8. doi: 10.1245/s10434-014-4365-3. Epub 2015 Jan 27. Ann Surg Oncol. 2015. PMID: 25623598
-
Hepatobiliary cancers, version 2.2014.J Natl Compr Canc Netw. 2014 Aug;12(8):1152-82. doi: 10.6004/jnccn.2014.0112. J Natl Compr Canc Netw. 2014. PMID: 25099447
-
[Recent progress in molecular targeted therapies for intrahepatic cholangiocarcinoma].Zhonghua Wai Ke Za Zhi. 2020 Apr 1;58(4):289-294. doi: 10.3760/cma.j.cn112139-20200128-00048. Zhonghua Wai Ke Za Zhi. 2020. PMID: 32241059 Review. Chinese.
-
Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis.Ann Surg Oncol. 2013 Nov;20(12):3779-86. doi: 10.1245/s10434-013-3127-y. Epub 2013 Jul 12. Ann Surg Oncol. 2013. PMID: 23846786
-
Cholangiocarcinoma.Crit Rev Oncol Hematol. 2009 Mar;69(3):259-70. doi: 10.1016/j.critrevonc.2008.09.008. Epub 2008 Nov 1. Crit Rev Oncol Hematol. 2009. PMID: 18977670 Review.
Cited by
-
HSF1 is a prognostic determinant and therapeutic target in intrahepatic cholangiocarcinoma.J Exp Clin Cancer Res. 2024 Sep 6;43(1):253. doi: 10.1186/s13046-024-03177-7. J Exp Clin Cancer Res. 2024. PMID: 39243039 Free PMC article.
-
Time-trends in liver cancer incidence and mortality rates in the U.S. from 1975 to 2017: a study based on the Surveillance, Epidemiology, and End Results database.J Gastrointest Oncol. 2023 Feb 28;14(1):312-324. doi: 10.21037/jgo-23-25. Epub 2023 Feb 23. J Gastrointest Oncol. 2023. PMID: 36915450 Free PMC article.
-
Effect of age on the prognosis of intrahepatic cholangiocarcinoma.Korean J Intern Med. 2023 Jan;38(1):39-47. doi: 10.3904/kjim.2022.146. Epub 2022 Dec 21. Korean J Intern Med. 2023. PMID: 36541019 Free PMC article.
-
Ferroptosis in Intrahepatic Cholangiocarcinoma: IDH1105GGT Single Nucleotide Polymorphism Is Associated With Its Activation and Better Prognosis.Front Med (Lausanne). 2022 Jul 8;9:886229. doi: 10.3389/fmed.2022.886229. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35872783 Free PMC article.
-
Eukaryotic Translation Initiation Factor 5A Independently Predicts Poor Prognosis of Cholangiocarcinoma Patients and Regulates the Ferroptosis and Mitochondrial Apoptosis.J Oncol. 2022 Jul 15;2022:4250531. doi: 10.1155/2022/4250531. eCollection 2022. J Oncol. 2022. PMID: 35874632 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical